Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) - Equities research analysts at Zacks Research dropped their Q1 2025 EPS estimates for Charles River Laboratories International in a research report issued on Tuesday, December 24th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $2.35 for the quarter, down from their previous forecast of $2.42. The consensus estimate for Charles River Laboratories International's current full-year earnings is $10.18 per share. Zacks Research also issued estimates for Charles River Laboratories International's FY2025 earnings at $9.99 EPS, Q1 2026 earnings at $2.75 EPS, Q3 2026 earnings at $2.87 EPS and FY2026 earnings at $11.60 EPS.
Several other analysts have also commented on CRL. StockNews.com lowered shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Thursday, November 7th. Citigroup cut Charles River Laboratories International from a "neutral" rating to a "sell" rating and cut their price target for the stock from $215.00 to $175.00 in a report on Tuesday, October 1st. UBS Group upped their price objective on Charles River Laboratories International from $240.00 to $250.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Bank of America dropped their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a research report on Friday, December 13th. Finally, Robert W. Baird reduced their target price on shares of Charles River Laboratories International from $191.00 to $190.00 and set a "neutral" rating on the stock in a report on Friday, September 20th. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $214.00.
Check Out Our Latest Analysis on CRL
Charles River Laboratories International Price Performance
Shares of NYSE:CRL traded down $0.49 during midday trading on Friday, hitting $186.16. 514,677 shares of the stock were exchanged, compared to its average volume of 616,023. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The stock has a market cap of $9.52 billion, a P/E ratio of 23.30, a PEG ratio of 5.00 and a beta of 1.38. The company has a 50 day moving average price of $193.06 and a 200-day moving average price of $201.23. Charles River Laboratories International has a twelve month low of $176.48 and a twelve month high of $275.00.
Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.43 by $0.16. The firm had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. Charles River Laboratories International's revenue was down 1.6% on a year-over-year basis. During the same period in the previous year, the firm posted $2.72 earnings per share.
Insider Activity
In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the business's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the transaction, the director now owns 12,386 shares in the company, valued at $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 1.30% of the company's stock.
Institutional Investors Weigh In On Charles River Laboratories International
Several hedge funds have recently modified their holdings of CRL. Bank of New York Mellon Corp lifted its position in shares of Charles River Laboratories International by 25.1% during the second quarter. Bank of New York Mellon Corp now owns 480,342 shares of the medical research company's stock worth $99,229,000 after purchasing an additional 96,319 shares in the last quarter. Whittier Trust Co. of Nevada Inc. grew its stake in shares of Charles River Laboratories International by 219.3% during the second quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company's stock valued at $58,000 after acquiring an additional 193 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in shares of Charles River Laboratories International by 1.0% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 206,014 shares of the medical research company's stock worth $42,558,000 after acquiring an additional 1,970 shares during the last quarter. Fort Washington Investment Advisors Inc. OH boosted its holdings in Charles River Laboratories International by 41.3% in the second quarter. Fort Washington Investment Advisors Inc. OH now owns 1,300 shares of the medical research company's stock valued at $269,000 after purchasing an additional 380 shares during the last quarter. Finally, iA Global Asset Management Inc. purchased a new stake in Charles River Laboratories International during the 2nd quarter worth approximately $87,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.
Charles River Laboratories International Company Profile
(
Get Free Report)
Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).
Featured Stories
Before you consider Charles River Laboratories International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.
While Charles River Laboratories International currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.